Filing Details

Accession Number:
0001415889-23-011348
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-07-19 18:00:32
Reporting Period:
2023-07-17
Accepted Time:
2023-07-19 18:00:32
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1798749 Aerovate Therapeutics Inc. AVTE () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1185035 P Timothy Noyes C/O Aerovate Therapeutics, Inc.
930 Winter Street, Suite M-500
Waltham MA 02451
Chief Executive Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-07-17 4,522 $2.14 4,522 No 4 M Direct
Common Stock Disposition 2023-07-17 4,522 $18.11 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2023-07-17 4,522 $0.00 4,522 $2.14
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
388,859 2031-04-01 No 4 M Direct
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2023.
  2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.00 to $18.525, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
  3. A total of 493,381 shares subject to an employee stock option were granted on April 2, 2021, with 25% vested on June 4, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter.